Lithospermate B

Research use only, not for human use.

Lithospermate B is a natural product activates eNOS and ameliorates endothelial dysfunction in diabetes by enhancing vasodilation in addition to reducing oxidative stress, it can protecte cardiomyocytes from ischemic injury through specific inhibition of TAB1-p38 apoptosis signaling.

Lithospermate B is a natural product activates eNOS and ameliorates endothelial dysfunction in diabetes by enhancing vasodilation in addition to reducing oxidative stress, it can protecte cardiomyocytes from ischemic injury through specific inhibition of TAB1-p38 apoptosis signaling.improves renal failure.magnesium lithospermate B (MLB) dose-dependently inhibited the activation of microglia and reduced neuronal apoptosis.?Western blot analysis showed that MLB decreased the expression of inflammatory cytokine TNF- and pro-apoptotic protein cleaved caspase-3.?More importantly, MLB increased the expression of SIRT1, while inhibited the acetylation of NF-B.?Furthermore, pretreatment with sirtinol (a selective inhibitor of SIRT1) reversed all the aforementioned effects of MLB after SAH.?magnesium lithospermate B (MLB), a bioactive ingredient extracted from Salvia miltiorrhiza, exerts neuroprotective effects in several central nervous system insults.administration of MLB significantly attenuated brain edema and neurological deficits after SAH.

Magnesium Lithospermate B (20-60 μg/ml; 24 h) decreases LDH activity in the cultured supernatant, increases SOD activity in cardiomyocytes, reduces intracellular ROS and MDA levels, and significantly suppresses cardiomyocytes apoptosis.Magnesium Lithospermate B (1-100 μg/ml) enhances proliferation of neural stem cells (NSCs) in a dose-dependent manner.Magnesium Lithospermate B (10 μg/ml) promotes the di?erentiation in vitro of NSCs towards neurons.

Magnesium Lithospermate B (2-8 mg/kg; p.o. once daily for 16 d) reduces the renal damage of oxidative stress through reduction of reactive oxygen species in old rats.Magnesium Lithospermate B (0.5 μg/g; s.c. for 6 weeks) promotes the neurogenesis and improves the memory in PD models. Animal Model:Young (5-month-old) and old (20-month-old) specific-pathogen-free male Sprague-Dawley rats Dosage:2, 8 mg/kg Administration:P.o. once daily for 16 days Result:Reduced the protein expression of major subunits of nicotinamide adenine dinucleotide phosphate oxidase (Nox4 and p22phox), phospho-p38, nuclear factor-kappa B p65, cyclooxygenase-2, and inducible nitric oxide synthase.Showed lower levels of senescence-related proteins such as p16, ADP-ribosylation factor 6, p53, and p21.

Monomethyl lithospermate B

Others

Other Targets

Others

——

——

122021-74-3

740.9

C36H28MgO16

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (67.49 mM)

[Mg++].Oc1ccc(\C=C\C(=O)OC(Cc2ccc(O)c(O)c2)C([O-])=O)c2C(C(Oc12)c1ccc(O)c(O)c1)C(=O)OC(Cc1ccc(O)c(O)c1)C([O-])=O

——

(-20℃)

With Ice Pack

≥ 2 years